Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib.
B-cell malignancies
atrial fibrillation
echocardiography
ibrutinib
left atrial strain
tyrosine kinase inhibitor
Journal
Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
08
2020
revised:
20
10
2020
accepted:
15
11
2020
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
8
7
2021
Statut:
ppublish
Résumé
Ibrutinib is associated with atrial fibrillation (AF), though echocardiographic predictors of AF have not been studied in this population. We sought to determine whether left atrial (LA) strain on transthoracic echocardiography could identify patients at risk for developing ibrutinib-related atrial fibrillation (IRAF). We performed a retrospective review of 66 patients who had an echocardiogram prior to ibrutinib treatment. LA strain was measured with TOMTEC Imaging Systems, obtaining peak atrial longitudinal strain (PALS) and peak atrial contraction strain (PACS) on 4-chamber and 2-chamber views. Statistical analysis was performed with chi-square analysis, t test, or binomial regression analysis, with a P-value < .05 considered statistically significant. Twenty-two patients developed IRAF (33%). Age at initiation of ibrutinib was significantly associated with IRAF (65.1 years vs 74.1 years, P = .002). Mean ibrutinib dose was lower among patients who developed IRAF (388.2 ± 121.7 vs 448.6 ± 88.4, P = .025). E/e' was significantly higher among patients who developed IRAF (11.5 vs 9.3, P = .04). PALS was significantly lower in patients who developed AF (30.3% vs 36.3%, P = .01). On multivariate regression analysis, age, PALS, and PACS were significantly associated with IRAF. On multivariate regression analysis, only PACS remained significantly associated with IRAF while accounting for age. Age, ibrutinib dose, E/e', and PALS on pre-treatment echocardiogram were significantly associated with development of IRAF. On multivariate regression analyses, age, PALS, and PACS remained significantly associated with IRAF. Impaired LA mechanics add to the assessment of patients at risk for IRAF.
Sections du résumé
BACKGROUND
Ibrutinib is associated with atrial fibrillation (AF), though echocardiographic predictors of AF have not been studied in this population. We sought to determine whether left atrial (LA) strain on transthoracic echocardiography could identify patients at risk for developing ibrutinib-related atrial fibrillation (IRAF).
METHODS
We performed a retrospective review of 66 patients who had an echocardiogram prior to ibrutinib treatment. LA strain was measured with TOMTEC Imaging Systems, obtaining peak atrial longitudinal strain (PALS) and peak atrial contraction strain (PACS) on 4-chamber and 2-chamber views. Statistical analysis was performed with chi-square analysis, t test, or binomial regression analysis, with a P-value < .05 considered statistically significant.
RESULTS
Twenty-two patients developed IRAF (33%). Age at initiation of ibrutinib was significantly associated with IRAF (65.1 years vs 74.1 years, P = .002). Mean ibrutinib dose was lower among patients who developed IRAF (388.2 ± 121.7 vs 448.6 ± 88.4, P = .025). E/e' was significantly higher among patients who developed IRAF (11.5 vs 9.3, P = .04). PALS was significantly lower in patients who developed AF (30.3% vs 36.3%, P = .01). On multivariate regression analysis, age, PALS, and PACS were significantly associated with IRAF. On multivariate regression analysis, only PACS remained significantly associated with IRAF while accounting for age.
CONCLUSIONS
Age, ibrutinib dose, E/e', and PALS on pre-treatment echocardiogram were significantly associated with development of IRAF. On multivariate regression analyses, age, PALS, and PACS remained significantly associated with IRAF. Impaired LA mechanics add to the assessment of patients at risk for IRAF.
Identifiants
pubmed: 33594858
doi: 10.1111/echo.14946
pmc: PMC7931636
mid: NIHMS1673617
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-88Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Hematol Oncol. 2018 Oct;36(4):624-632
pubmed: 29512173
J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678
pubmed: 31558250
Cardiovasc Ultrasound. 2009 Feb 08;7:6
pubmed: 19200402
JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500
pubmed: 30573111
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Leuk Lymphoma. 2019 Jun;60(6):1447-1453
pubmed: 30730240
Blood. 2014 Dec 11;124(25):3829-30
pubmed: 25498454
Cureus. 2018 May 29;10(5):e2701
pubmed: 30062075
Heart Rhythm. 2019 Sep;16(9):1374-1382
pubmed: 30959203
Leuk Lymphoma. 2018 Feb;59(2):311-320
pubmed: 28629235
Blood Adv. 2017 Sep 08;1(20):1739-1748
pubmed: 29296820
Int J Cardiol. 2016 Oct 1;220:535-7
pubmed: 27390983
Cardiovasc Ultrasound. 2012 Dec 03;10:48
pubmed: 23199055
J Am Coll Cardiol. 2011 Jan 18;57(3):324-31
pubmed: 21232671
Open Heart. 2019 May 8;6(1):e001049
pubmed: 31168393
Heart Fail Rev. 2016 Jan;21(1):65-76
pubmed: 26687372
Haematologica. 2017 Oct;102(10):1796-1805
pubmed: 28751558
Eur Heart J Cardiovasc Imaging. 2016 Oct;17(10):1153-60
pubmed: 26710819
J Hematol Oncol. 2018 Jun 11;11(1):79
pubmed: 29891001
J Am Soc Echocardiogr. 2017 Jan;30(1):59-70.e8
pubmed: 28341032
Leuk Lymphoma. 2017 Dec;58(12):2811-2814
pubmed: 28504030
Int J Cardiol. 2016 Oct 1;220:208-13
pubmed: 27389443
Blood. 2016 Jul 7;128(1):138-40
pubmed: 27247135
J Am Soc Echocardiogr. 2011 May;24(5):513-9
pubmed: 21353469